Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial.

The rate of CSEs requiring hospitalisation (excluding ED visits) was also reduced in the mepolizumab group; however, this was the only secondary end-point reported that did not reach statistical significance, which may be attributed to the low number of events across both groups.

also in 111,027 other papers